Page 3 - Activity Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Activity score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Activity Score Today - Breaking & Trending Today

Viridian Announces Positive Data from Ongoing Phase 1/2

- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg. ....

United States , Roger Turbin , Barrett Katz , Todd James , Neither The Company , Drug Administration , Company Annual Report On Form , Exchange Commission , Viridian Therapeutics Inc , Corporate Affairs , Clinical Activity Score , Visual Science , Rutgers New Jersey Medical School , Activity Score , Chief Medical Officer , Thyroid Eye Disease Pipeline , Private Securities Litigation Reform Act , Annual Report , Vice President , Viridian Therapeutics , Nasdaq Vrdn , Viridian Therapeutics ,

Efruxifermin Led to NASH Resolution, Fibrosis Improvement in Mid-Stage Trial

Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH ....

United States , Zaina Hamza , Medpage Today , Activity Score , 28 Mg ,

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting - Viridian Therapeutics (NASDAQ:VRDN) - Press Release

- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation ....

United States , Barrett Katz , Shoaib Ugradar , Kelly Foster , Brent Dickinson , Yang Zhao , Rochelle Summerfelt , John Jordan , Denis Oshaughnessy , Rachel Newell , Raymond Douglas , Neither The Company , Sinai Medical Center , Cedars Sinai Medical Center , Development For Thyroid Eye Disease , Stein Eye Institute , American Thyroid Association , Exchange Commission , Company Annual Report On Form , Corporate Communications , Viridian Therapeutics Inc , Thyroid Eye Disease Program , Viridian Therapeutics , Full Antagonist Antibody , Insulin Like Growth Factor , Thyroid Eye Disease ,

Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

/PRNewswire/ Regeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today preliminary Phase 1 data supporting. ....

United Kingdom , Christine Regan Lindenboom , Alexandra Bowie , Kevin Sloan , Josh Brodsky , Aris Baras , Vesna Tosic , Alnylam Pharmaceuticals Inc , Prnewswire Regeneron Pharmaceuticals , Teva Pharmaceutical Industries Ltd , Alnylam Pharmaceuticals , Development Programs , Head Of The Regeneron Genetics Center , Regeneron Pharmaceuticals Inc , Regeneron Genetics Center , Exchange Commission , Program Leader , Clinical Research Network , Activity Score , Vice President , Senior Vice President , Regeneron Genetics , Research Network , Enhanced Stabilization Chemistry Plus , Nobel Prize Winning , Private Securities Litigation Reform Act ,

Novel anti-IGF-1R antibody promising treatment for Thyroid Eye Disease in clinical trial

An anti-IGF-1R antibody VRDN-001developed by Viridian Therapeutics has succeeded in a phase I/II clinical trial of people with active thyroid eye disease, with participants seeing an average 2.4 mm. ....

Barrett Katz , Raymond Douglas , Sinai Medical Center , Thyroid Eye Disease Program , Viridian Therapeutics , Clinical Activity Score , Cedars Sinai Medical Center , Activity Data , Activity Score , Gorman Subjective Diplopia , Chief Medical Officer , Vrdn 001 , Igf 1r , Thyroid Eye Disease , Ted Patients , Eye Disease , Ted Treatment ,